Myc Proto Oncogene Protein - Drugs In Development, 2021
Myc Proto Oncogene Protein - Drugs In Development, 2021
SUMMARY
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Myc Proto Oncogene Protein - Drugs In Development, 2021, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Colon Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Myc Proto Oncogene Protein - Drugs In Development, 2021, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Colon Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
Anima Biotech Inc
Arvinas Inc
Biogenera SpA
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYCTX Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc
TheraMyc Ltd
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
Amy-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MYC for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-4000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-19077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0162977 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Myc and Ubiquitin Protein Ligase for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMyc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and TOP1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
Featured News & Press Releases
May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial
Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial
Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
Mar 14, 2019: A new approach to drugging a difficult cancer target
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
Anima Biotech Inc
Arvinas Inc
Biogenera SpA
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYCTX Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc
TheraMyc Ltd
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
Amy-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MYC for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-4000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-19077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0162977 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Myc and Ubiquitin Protein Ligase for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMyc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and TOP1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
Featured News & Press Releases
May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial
Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial
Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
Mar 14, 2019: A new approach to drugging a difficult cancer target
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Anima Biotech Inc, 2021
Pipeline by Arvinas Inc, 2021
Pipeline by Biogenera SpA, 2021
Pipeline by Escend Pharmaceuticals Inc, 2021
Pipeline by Gibson Oncology LLC, 2021
Pipeline by Kintor Pharmaceutical Ltd, 2021
Pipeline by Kronos Bio Inc, 2021
Pipeline by MecRx Pty Ltd, 2021
Pipeline by OncoViRx LLC, 2021
Pipeline by Origenis GmbH, 2021
Pipeline by Peptomyc SL, 2021
Pipeline by PYCTX Ltd, 2021
Pipeline by Recursion Pharmaceuticals Inc, 2021
Pipeline by Sapience Therapeutics Inc, 2021
Pipeline by SyntheX Inc, 2021
Pipeline by TheraMyc Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Anima Biotech Inc, 2021
Pipeline by Arvinas Inc, 2021
Pipeline by Biogenera SpA, 2021
Pipeline by Escend Pharmaceuticals Inc, 2021
Pipeline by Gibson Oncology LLC, 2021
Pipeline by Kintor Pharmaceutical Ltd, 2021
Pipeline by Kronos Bio Inc, 2021
Pipeline by MecRx Pty Ltd, 2021
Pipeline by OncoViRx LLC, 2021
Pipeline by Origenis GmbH, 2021
Pipeline by Peptomyc SL, 2021
Pipeline by PYCTX Ltd, 2021
Pipeline by Recursion Pharmaceuticals Inc, 2021
Pipeline by Sapience Therapeutics Inc, 2021
Pipeline by SyntheX Inc, 2021
Pipeline by TheraMyc Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
